Arrowhead Pharmaceuticals (ARWR) to Announce Quarterly Earnings on Tuesday

Arrowhead Pharmaceuticals (NASDAQ:ARWR) is anticipated to release its Q3 2026 results after the market closes on Tuesday, August 4th. Analysts expect the company to post earnings of ($1.2767) per share and revenue of $44.1730 million for the quarter. Individuals can find conference call details on the company’s upcoming Q3 2026 earning overview page for the latest details on the call scheduled for Tuesday, August 4, 2026 at 4:30 PM ET.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last released its earnings results on Thursday, May 7th. The biotechnology company reported ($0.93) EPS for the quarter, beating the consensus estimate of ($1.10) by $0.17. Arrowhead Pharmaceuticals had a negative net margin of 48.38% and a negative return on equity of 55.09%. The firm had revenue of $73.74 million for the quarter, compared to analysts’ expectations of $73.84 million. During the same quarter last year, the company earned $2.75 EPS. Arrowhead Pharmaceuticals’s quarterly revenue was down 86.4% on a year-over-year basis. On average, analysts expect Arrowhead Pharmaceuticals to post $-3 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Arrowhead Pharmaceuticals Price Performance

Shares of NASDAQ ARWR traded down $1.80 during mid-day trading on Tuesday, reaching $83.73. 565,070 shares of the company traded hands, compared to its average volume of 2,485,678. Arrowhead Pharmaceuticals has a fifty-two week low of $15.01 and a fifty-two week high of $95.49. The firm has a market cap of $11.79 billion, a PE ratio of -38.97 and a beta of 1.26. The stock has a fifty day simple moving average of $78.17 and a 200-day simple moving average of $70.12. The company has a debt-to-equity ratio of 1.41, a current ratio of 6.23 and a quick ratio of 6.23.

Insider Activity at Arrowhead Pharmaceuticals

In related news, Director Hongbo Lu sold 2,970 shares of the firm’s stock in a transaction on Tuesday, May 12th. The stock was sold at an average price of $76.88, for a total value of $228,333.60. Following the completion of the transaction, the director directly owned 52,012 shares of the company’s stock, valued at $3,998,682.56. This trade represents a 5.40% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 3.60% of the company’s stock.

Institutional Investors Weigh In On Arrowhead Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the stock. iSAM Funds UK Ltd bought a new position in Arrowhead Pharmaceuticals during the 3rd quarter valued at about $29,000. Daiwa Securities Group Inc. raised its position in shares of Arrowhead Pharmaceuticals by 883.3% during the second quarter. Daiwa Securities Group Inc. now owns 4,189 shares of the biotechnology company’s stock worth $66,000 after acquiring an additional 3,763 shares during the last quarter. Lazard Asset Management LLC bought a new stake in Arrowhead Pharmaceuticals during the 2nd quarter worth about $91,000. Quadrant Capital Group LLC bought a new stake in shares of Arrowhead Pharmaceuticals during the third quarter worth approximately $140,000. Finally, State of Wyoming acquired a new position in shares of Arrowhead Pharmaceuticals in the 2nd quarter valued at $142,000. 62.61% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on ARWR shares. HC Wainwright lifted their price target on Arrowhead Pharmaceuticals from $100.00 to $115.00 and gave the stock a “buy” rating in a research note on Monday. Sanford C. Bernstein increased their price target on shares of Arrowhead Pharmaceuticals from $35.00 to $46.00 and gave the stock a “market perform” rating in a research report on Wednesday, May 13th. Piper Sandler restated an “overweight” rating and set a $126.00 price target (up from $110.00) on shares of Arrowhead Pharmaceuticals in a report on Thursday, July 23rd. Royal Bank Of Canada boosted their price target on shares of Arrowhead Pharmaceuticals from $80.00 to $87.00 and gave the company an “outperform” rating in a report on Friday, May 8th. Finally, Leerink Partners increased their price objective on Arrowhead Pharmaceuticals from $61.00 to $72.00 and gave the stock a “market perform” rating in a report on Wednesday, June 17th. Nine analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Arrowhead Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus price target of $95.08.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.